Abstract:The identification of protective agents for the treatment of neurodegenerative diseases is the mainstay therapeutic goal to modify the disease course and arrest the irreversible disability progression. Pharmacological therapies synergistically targeting multiple pathogenic pathways, including oxidative stress, mitochondrial dysfunction, and inflammation, are prime candidates for neuroprotection. Combination or synergistic therapy with melatonin, whose decline correlates with altered sleep/wake cycle and impaired glymphatic "waste clearance" system in neurodegenerative diseases, has a great therapeutic potential to treat inflammatory neurodegenerative states. Despite the protective outcomes observed in preclinical studies, mild or poor outcomes were observed in clinical settings, suggesting that melatonin combinations promoting synergistic actions at appropriate doses might be more suitable to treat multifactorial neurodegenerative disorders. In this review, we first summarize the key melatonin actions and pathways contributing to cell protection and its therapeutic implication in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We remark the major controversies in the field, mostly generated by the lack of a common consensus for the optimal dosing, molecular targets, and toxicity. Then, we review the literature investigating the efficacy of melatonin combinations with approved or investigational neuroprotective agents and of melatonin‐containing hybrid molecules, both in vitro and in animal models of AD, PD, and MS, as well as the efficacy of add‐on melatonin in clinical settings. We highlight the rationale for such melatonin combinations with a focus on the comparison with single‐agent treatment and on the assays in which an additive or a synergistic effect has been achieved. We conclude that a better characterization of the mechanisms underlying such melatonin synergistic actions under neuroinflammation at appropriate doses needs to be tackled to advance successful clinical translation of neuroprotective melatonin combination therapies or melatonin‐based hybrid molecules.

Melatonin: Regulation of Biomolecular Condensates in Neurodegenerative Disorders

Melatonin and phase separation: potential interactions and significance

Biomolecular condensates and disease pathogenesis

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance

Brain washing and neural health: role of age, sleep, and the cerebrospinal fluid melatonin rhythm

Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology

Molecular mechanisms of melatonin-induced alleviation of synaptic dysfunction and neuroinflammation in Parkinson's disease: a review

Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases

Structural Insight into Melatonin's Influence on the Conformation of Aβ42 Dimer Studied by Molecular Dynamics Simulation

Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin

Oxidative Toxicity in Models of Neurodegeneration: Responses to Melatonin

Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases

Localized surface plasmon resonance and atomic force microscopy study of model lipid membranes and their interactions with amyloid and melatonin

Melatonin and biological membrane bilayers: a never ending amity

Dysfunctional mitochondria in age-related neurodegeneration: Utility of melatonin as an antioxidant treatment

Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics

The Mechanism of Protein Condensation in Neurodegenerative Diseases

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications

Melatonin: A potential nighttime guardian against Alzheimer's